Biotechnology company Advanced Enzyme Technologies announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations on consolidated basis decreased to Rs 1,461 million in the Q2FY25 from Rs 1,578 million in the Q2FY24, a de-growth of 7%. Consolidated EBITDA during Q2FY25 stands at Rs 424 million as compared to Rs 513 million during Q2FY24, decrease of 17%. Profit before tax stands at Rs 422 million during Q2FY25 as against Rs 479 million in Q2FY24, decrease of 12%. Profit after tax de-grew by 5% and stands at Rs 334 million during Q2FY25 as compared to Rs 352 million during the Q2FY24. EBITDA margin stands at 29%, PBT margin stands at 29% and PAT margin stands at 23% during the quarter. Financial costs stood at Rs 9 million during Q2FY25 as against Rs 7 million in Q2FY24. Depreciation and Amortization charge for the Q2FY25 stood at Rs 89 million as compared to Rs 87 million Q2FY24. Earnings Per Share during Q2FY25 stands at Rs 2.94 as compared to Rs 3.08 in Q2FY24. H1FY25 Financial Highlights: Revenue from operations on consolidated basis decreased to Rs 3,006 million in the H1FY25 from Rs 3,051 million in the H1FY24, reported decrease of 1%. Consolidated EBITDA during H1FY25 stands at Rs 936 million as compared to Rs 953 million during H1FY24, de-growth of 2%. Profit before tax stands at Rs 909 million during H1FY25 as against Rs 893 million in H1FY24, an increase of 2%. Profit after tax stands at Rs 684 million during H1FY25 as compared to Rs 646 million during the H1FY24, an increase of 6%.. EBITDA margin stands at 31%, PBT margin stands at 30% and PAT margin stands at 23% during the H1FY25. Financial costs stood at Rs 18 million during H1FY25 as against Rs 14 million in H1FY24. Depreciation and Amortization charge for the H1FY25 is Rs 175 million as compared to Rs 174 million in H1FY24. Earnings Per Share during H1FY25 stands at Rs 5.99 as compared to Rs 5.65 in H1FY24. Result PDF